EDVP Parallax Health Sciences

Parallax Behavioral Health Achieves Data Driven Outcomes Adoption and Vertical Market Integration

Parallax Behavioral Health Achieves Data Driven Outcomes Adoption and Vertical Market Integration

SANTA MONICA, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Parallax Health Sciences, Inc. (OTCQB: PRLX) (''Parallax'' or the ''Company''), an outcome-driven connected healthcare company, today announced its wholly-owned subsidiary Parallax Behavioral Health, Inc. has entered into vertical market licenses and technology integration agreements within the financial technology, human resource, lifestyle and healthcare fields. 

”Our data driven outcomes technology has application within several identified fields of use and we are fulfilling our commitment to our intellectual property monetization strategy by generating high gross margin revenue through licensing and enabling leading organizations with our technology to maximize our shareholder value,” commented Paul Arena, Chief Executive Officer of Parallax Health Sciences, Inc. Mr. Arena continued, “We’ve expanded our approach to marketing our technology solutions through a business to business strategy that allows us to develop revenues from technology provisioning, licensing and royalty agreements that strengthen our patents and proves out efficacy within large and highly scalable markets.”

“By empowering leading companies to utilize our patented technology and platform we are establishing the value of Parallax Behavioral Healthcare in use cases where our data driven outcomes technology is measured and improved through timely interventions,” stated Nathaniel Bradley, Chief Technology Officer of Parallax Health Sciences, Inc.  Mr. Bradley added, “Understanding human behavior through measurement and how to change it from leading organizations with proven methods is a formula for our successful and automated scale.  As we establish our patented technology’s use in these vertical markets, we are also able to begin to better understand, define and value the infringement activities within each vertical. Our patent enforcement initiatives are enriched through this activity.”

About Parallax Behavioral Health

Parallax Behavioral Health (PBH) provides consulting and software solutions to businesses and individuals to improve value, margin and performance though enhanced outcomes and lower cost mastery. With its patented Intrinsic Code, which encompasses predictive and progressive analytics combined with its goal optimization software, PBH is strategically positioned to enable users from large healthcare corporations to individuals to take control of their outcomes.

About Parallax Health Sciences

Parallax Health Sciences is an advanced technology, outcome-driven telehealth company that allows for cost-effective remote diagnosis, treatment and monitoring of patients through proprietary platforms of integrated products and services. The Company's interoperable novel applications provide patients point-of-care testing and monitoring with information communicated via internet-based mobile phone applications that are agnostic as to operating system and are built on highly sophisticated data analytics. Information is retrieved real-time by physicians who are monitoring patients with chronic diseases or through biometric feedback for health-related behavior modification and is automated for integration into electronic health records. The Company's products and offerings capitalize on the digital transformation in healthcare for improved patient compliance, diagnosis and treatment, and support healthcare system cost savings and efficiencies. For more information, please visit or .

Forward-Looking Statements

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our Form 10-K and other reports filed with the SEC. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact:
Paul Arena

 

Mobile 404-915-8449
EN
12/11/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Parallax Health Sciences

 PRESS RELEASE

Parallax Health Sciences Announces Increased Customer Acquisition in B...

Parallax Health Sciences Announces Increased Customer Acquisition in Both Management and Diagnostics Divisions Company Receives Over $10 million of Telehealth and Medical Supply Contracts from Coast to Coast  NEW YORK, NY, April 09, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Parallax Health Sciences, Inc. (OTCQB: PRLX) (“Parallax” or the “Company”), an outcome-driven connected healthcare company, today announced that its Parallax Health Management and Parallax Diagnostics divisions have added customer accounts within the U.S. healthcare industry.  Contracts from home healthcare, ...

 PRESS RELEASE

Parallax Diagnostics Partners with CURE Pharmaceuticals to Distribute ...

Parallax Diagnostics Partners with CURE Pharmaceuticals to Distribute Individually Sealed CUREfilm® D for Medical and Critical Services Workers  COVID-19 Coronavirus Infection Risk May be Reduced by Weekly Dose of Vitamin D3 NEW YORK, NY, April 07, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Parallax Health Sciences, Inc. (OTCQB: PRLX) (“Parallax” or the “Company”), announced that its wholly owned subsidiary Parallax Diagnostics, Inc. has contracted with CURE Pharmaceutical Holding Corp. to distribute CUREfilm® D. The supplement that provides a single wrapped CUREfilm® that de...

 PRESS RELEASE

Parallax Announces International Medical Supply Chain Agreement for CO...

Parallax Announces International Medical Supply Chain Agreement for COVID-19 Testing Kits and FDA Registered Suppliers of Personal Protective Equipment (PPE) Joint Venture Procures from Established Manufacturers with Reliable Supply and Logistics for US Medical Operations NEW YORK, NY, March 30, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Parallax Health Sciences, Inc. (OTCQB: PRLX) (''Parallax'' or the ''Company''), an outcome-driven connected healthcare company, today announced its wholly-owned subsidiary, Parallax Diagnostics, Inc., has executed a joint venture agreement with the Un...

 PRESS RELEASE

Parallax Launches Secure Good Health Outcomes Telehealth Application f...

Parallax Launches Secure Good Health Outcomes Telehealth Application for Immediate Free Download Parallax Announces Patented Telehealth Initiative to Help Healthcare Providers Better Communicate with Their Patients and Reduce ER Admissions NEW YORK, NY, March 25, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Parallax Health Sciences, Inc. (OTCQB: PRLX) (''Parallax'' or the ''Company''), an outcome-driven connected healthcare company, today announced that its Good Health OutcomesTM Telehealth, diagnostic and Remote Patient Monitoring Mobile App is available for immediate download at zer...

 PRESS RELEASE

Parallax Updates Progress on Proprietary COVID-19 Rapid Test

Parallax Updates Progress on Proprietary COVID-19 Rapid Test Parallax Acquired Antigen And Antibodies Of COVID-19 Being Integrated Into Its Patented And FDA Approved Target Diagnostics Test Platform NEW YORK, New York, March 24, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Parallax Health Sciences, Inc. (OTCQB: PRLX) (''Parallax'' or the ''Company''), an outcome-driven connected healthcare company, today announced that it has selected the antigens and antibodies that it will use as the markers for its rapid Coronavirus (“COVID-19”) screen test used on its FDA Cleared & Patented Target Di...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch